🔍

JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM)

📊 NSE: JBCHEPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 08 Jul 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q4 FY26)

In its latest reported quarter, Q4 FY26, JB Chemicals' revenue was ₹904 Cr (-4.8% year on year, -15.1% on the previous quarter), and net profit ₹101 Cr (-30.7% year on year); the operating margin was 22.2%.

Q4 FY26 (₹ Cr)	Value	YoY vs Q4 FY25	QoQ
Revenue	₹904	-4.8%	-15.1%
Operating profit	₹201	-11.2%	-32.1%
Net profit	₹101	-30.7%	-49.0%
EPS (₹)	6.31	-32.6%	-50.0%
Operating margin	22.2%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

JB Chemicals Amalgamates with Torrent Pharma; Scheme Effective July 8, 2026

🟢 POSITIVE ⭐ 10/10

M&A 📅 08 Jul 2026, 11:32 AM

JB Chemicals & Pharmaceuticals Limited has officially merged into Torrent Pharmaceuticals Limited, with the scheme becoming effective on July 8, 2026. This follows the filing of the NCLT Ahmedabad Bench's sanctioned order with the Registrar of Companies. Consequently, JB Chemicals, a company with a market capitalization of Rs 38,584 Cr and TTM revenue of Rs 4,148 Cr, stands dissolved without being wound up. The appointed date for this amalgamation is January 21, 2026.

Effective date of the amalgamation is July 8, 2026, following ROC filing.
Appointed date for the merger is set as January 21, 2026.
JB Chemicals (TTM Revenue Rs 4,148 Cr) stands dissolved as a separate legal entity.
NCLT Ahmedabad Bench sanctioned the scheme via an order dated July 6, 2026.
JB Chemicals' portfolio, including its 26.7% OPM business, will now be part of Torrent Pharma.

💡 Investors should watch for the announcement of the record date for the issuance of Torrent Pharma shares to JB Chemicals shareholders as per the approved swap ratio. Trading in JBCHEPHARM shares will be suspended shortly thereafter.

JB Chemicals Submits Quarterly Compliance Certificate for Dematerialization (June 2026)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jul 2026, 09:19 PM

JB Chemicals & Pharmaceuticals Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Datamatics Business Solutions Limited, confirms that share certificates received for dematerialization during the quarter ended June 30, 2026, were processed within the mandated 15-day timeframe. This is a standard administrative filing required for all listed companies to ensure the integrity of electronic shareholding records.

Compliance certificate issued for the quarter ended June 30, 2026
Securities received for dematerialization were processed within 15 days of receipt
Registrar and Share Transfer Agent confirmed as Datamatics Business Solutions Limited
Confirmation that physical certificates were mutilated and cancelled after verification

💡 This is a routine regulatory filing with no impact on business fundamentals. Investors should monitor the company's upcoming quarterly financial results for performance updates.

51:100 Swap Ratio: JB Chemicals Sets July 17 as Record Date for Merger with Torrent Pharma

🟢 POSITIVE ⭐ 10/10

M&A 📅 07 Jul 2026, 08:06 PM

JB Chemicals & Pharmaceuticals has announced July 17, 2026, as the record date for its merger into Torrent Pharmaceuticals Limited. Under the NCLT-sanctioned scheme, JB Chemicals shareholders will receive 51 fully paid-up equity shares of Torrent Pharma (FV ₹5) for every 100 shares of JB Chemicals (FV ₹1) held. This marks the final stages of the amalgamation process following the NCLT Ahmedabad Bench order dated July 6, 2026. The merger involves a company with a current market capitalization of ₹37,909 crore and TTM revenue of ₹4,148 crore.

Record date for the merger/amalgamation fixed as July 17, 2026
Share exchange ratio set at 51 Torrent Pharma shares for every 100 JB Chemicals shares
NCLT Ahmedabad Bench sanctioned the scheme via an order dated July 6, 2026
JB Chemicals reported TTM revenue of ₹4,148 crore and PAT of ₹709 crore prior to this final merger step
The merger combines JB Chemicals' ₹37,909 crore market cap entity into Torrent Pharmaceuticals

💡 Investors should monitor the share price of Torrent Pharmaceuticals, as JB Chemicals' stock will likely trade in tandem with the implied swap value (0.51x Torrent's price) until the record date. Ensure holdings are in demat by July 17 to qualify for the share allotment.

NCLT Sanctions Merger of JB Chemicals (Rs 37,909 Cr M-Cap) with Torrent Pharmaceuticals

🟢 POSITIVE ⭐ 10/10

M&A 📅 07 Jul 2026, 06:03 PM

JB Chemicals has received the certified copy of the NCLT Ahmedabad Bench order sanctioning its Scheme of Amalgamation with Torrent Pharmaceuticals Limited. This represents a total merger of the company (TTM Revenue: Rs 4,148 Cr) into Torrent Pharma. The order was passed on July 6, 2026, and received by the company on July 7, 2026. This is the final legal approval required to proceed with the dissolution of JB Chemicals as a separate entity and the issuance of shares in the merged entity to existing shareholders.

NCLT Ahmedabad Bench sanctioned the Scheme of Amalgamation on 6th July, 2026
Certified true copy of the order was received by the company on 7th July, 2026
JB Chemicals (Market Cap Rs 37,909 Cr) to be merged into Torrent Pharmaceuticals Limited
The merger involves a company with TTM Revenue of Rs 4,148 Cr and OPM of 26.7%
The scheme is being executed under Sections 230 to 232 of the Companies Act, 2013

💡 Monitor for the filing of the NCLT order with the Registrar of Companies (Form INC-28) and the subsequent announcement of the 'Record Date' for the share swap with Torrent Pharmaceuticals.

NCLT Sanctions Amalgamation of JB Chemicals with Torrent Pharmaceuticals

🟢 POSITIVE ⭐ 10/10

M&A 📅 06 Jul 2026, 06:49 PM

The Hon'ble NCLT, Ahmedabad Bench, has officially sanctioned the Scheme of Amalgamation of JB Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited on July 6, 2026. This merger involves JB Chemicals, a company with a market capitalization of Rs 37,054 Cr and TTM revenue of Rs 4,148 Cr, being absorbed by Torrent Pharma. The scheme will become effective once the certified copy of the NCLT order is filed with the Registrar of Companies (RoC). This consolidation combines JB's high-growth domestic portfolio with Torrent's larger scale.

NCLT Ahmedabad Bench sanctioned the merger scheme on July 6, 2026
JB Chemicals (Transferor) to merge into Torrent Pharmaceuticals (Transferee)
JB Chemicals brings TTM revenue of Rs 4,148 Cr and PAT of Rs 709 Cr to the combined entity
The company currently maintains a high OPM of 26.7% and ROCE of 25.0%
Effective date of merger is pending the filing of the certified order with the RoC

💡 Investors should watch for the announcement of the 'Record Date' for the issuance of Torrent Pharma shares to JB Chemicals shareholders. It is essential to review the share exchange ratio to understand the final value of the holding in the merged entity.

JB Chemicals Announces Trading Window Closure from July 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Jun 2026, 06:21 PM

JB Chemicals & Pharmaceuticals has announced the closure of its trading window for insiders starting July 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of the unaudited financial results for the quarter ending June 30, 2026. The window will remain closed until 48 hours after the board officially declares the quarterly results. This is a standard administrative procedure for all listed Indian companies and has no impact on business operations or financials.

Trading window closure effective from July 1, 2026
Closure pertains to the financial results for the quarter ending June 30, 2026
Window to reopen 48 hours after the board meeting results are announced
Compliance follows SEBI (Prohibition of Insider Trading) Regulations, 2015

💡 Educational: No action required. Investors should wait for the announcement of the board meeting date to know when the Q1 FY27 results will be released.

Retirement of President Global Business and VP-IT at JB Chemicals

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 30 Jun 2026, 06:07 PM

JB Chemicals & Pharmaceuticals has announced the retirement of two senior management personnel effective June 30, 2026. Mr. Pradeep Kumar Singh, President of Global Business, and Mr. Suresh Bhise, Vice President of IT, have ceased their roles. This transition is notable as the international segment accounts for approximately 39% of the company's TTM revenue of ₹4,148 Cr. The company has not yet disclosed immediate successors for these specific roles in this filing.

Mr. Pradeep Kumar Singh retired as President Global Business effective June 30, 2026
Mr. Suresh Bhise retired as Vice President – IT effective June 30, 2026
International business, previously under the Global Business head, represents 39% of total revenue
Company maintains a strong financial profile with TTM PAT of ₹709 Cr and 26.7% OPM

💡 Monitor for the appointment of a new President for Global Business to ensure continuity in the international segment, which is a critical growth pillar for the company.

JB Chemicals Shareholders Approve Rs 22 Total Dividend and FY26 Financials at 50th AGM

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 17 Jun 2026, 08:28 PM

JB Chemicals & Pharmaceuticals Limited held its 50th Annual General Meeting on June 17, 2026, where shareholders approved all proposed resolutions with a significant majority. Key approvals included the adoption of audited financial statements for the fiscal year ended March 31, 2026. Shareholders confirmed an interim dividend of Rs. 12.70 and approved a final dividend of Rs. 9.30, bringing the total dividend for FY26 to Rs. 22.00 per share. Additionally, the re-appointment of Mr. Amal Kelshikar as a Director was ratified with 99.84% support.

Shareholders approved a final dividend of Rs. 9.30 per share, resulting in a total dividend of Rs. 22.00 for FY26.
Adoption of standalone and consolidated audited financial statements for FY26 passed with nearly 100% of votes in favour.
Re-appointment of Mr. Amal Kelshikar as Director was approved with 133,790,983 votes in favour (99.84%).
Total voter turnout represented approximately 83.48% of the total outstanding shares for the dividend resolutions.

💡 Investors should take note of the total dividend payout of Rs. 22 per share, which reflects a stable return to shareholders. The high approval rates for all resolutions indicate strong institutional and promoter support for the current management and financial reporting.

JB Chemicals Shareholders Approve ₹22 Total Dividend and FY26 Financials at 50th AGM

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 17 Jun 2026, 08:14 PM

JB Chemicals & Pharmaceuticals Limited successfully concluded its 50th Annual General Meeting on June 17, 2026, with all resolutions passed by a requisite majority. Shareholders approved the adoption of standalone and consolidated financial statements for FY 2025-26 and confirmed a total dividend payout of ₹22 per share. This includes a previously paid interim dividend of ₹12.70 and a newly approved final dividend of ₹9.30 per equity share of face value ₹1. Institutional and promoter participation was high, with over 83% of total shares represented in the voting process.

Approved a final dividend of ₹9.30 per share, resulting in a total dividend of ₹22.00 for FY 2025-26.
Adoption of standalone and consolidated audited financial statements for the fiscal year ended March 31, 2026.
Re-appointment of Mr. Amal Kelshikar as Director, receiving 99.84% of the total votes in favor.
High institutional engagement with 90.48% of institutional shares polled for the dividend resolutions.
Total voter turnout stood at 83.48% of the company's 160,558,706 outstanding shares.

💡 Investors should welcome the confirmation of the ₹22 total dividend, which signals management's commitment to returning capital. The near-unanimous approval of all resolutions suggests strong institutional and retail confidence in the company's governance and strategic direction.

JB Chemicals EVP Supply Chain Bhushan Sachdev Resigns Effective June 12, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 15 Jun 2026, 05:55 PM

JB Chemicals & Pharmaceuticals Limited has confirmed the resignation of Mr. Bhushan Sachdev, who served as the Executive Vice President of Supply Chain Management. The resignation, cited for personal reasons, became effective as of the close of business on June 12, 2026. This disclosure follows a specific request from BSE Limited for a fresh announcement regarding the cessation of his role as Senior Management Personnel. The company has updated its records to reflect this change in its leadership structure.

Mr. Bhushan Sachdev has resigned from his role as Executive Vice President – Supply Chain Management.
The resignation became effective from the closing of business hours on June 12, 2026.
The departure is attributed to personal reasons rather than operational or performance issues.
The announcement was issued as a clarification following a query from BSE Limited on June 13, 2026.

💡 Investors should treat this as a routine management update; however, they may want to monitor for the appointment of a successor to ensure continuity in supply chain operations.

JB Chemicals Clarifies Authorization for Signing FY26 Financial Results

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 13 Jun 2026, 10:59 AM

JB Chemicals & Pharmaceuticals Limited has responded to a clarification sought by the National Stock Exchange regarding its financial results for the year ended March 31, 2026. The exchange had questioned the signing authority of the results originally submitted on May 11, 2026. The company clarified that the Board of Directors, in a meeting on May 11, 2026, specifically authorized Director Mr. Sudhir Menon to sign the standalone and consolidated financial statements. This filing provides the necessary board resolution to ensure compliance with SEBI (LODR) Regulations.

NSE sought clarification on May 20, 2026, regarding the financial results submitted on May 11, 2026.
The Board of Directors approved the audited standalone and consolidated financial results for FY ended March 31, 2026.
Mr. Sudhir Menon, Director, was formally authorized via a board resolution to sign the financial statements on behalf of the Board.
The company submitted a certified true copy of the resolution to the exchange to address the procedural query.

💡 No action is required from investors as this is a routine administrative clarification regarding procedural compliance and does not impact the company's financial performance.

JB Chemicals EVP Supply Chain Bhushan Sachdev Resigns Effective June 12, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 12 Jun 2026, 06:11 PM

JB Chemicals & Pharmaceuticals Limited has announced that Mr. Bhushan Sachdev, Executive Vice President – Supply Chain Management, has resigned from his position. The resignation is effective from the close of business hours on June 12, 2026. As a member of the Senior Management Personnel, his departure is disclosed in compliance with SEBI Regulation 30. The company has not yet named a successor for this critical operational role.

Mr. Bhushan Sachdev resigned as Executive Vice President – Supply Chain Management.
The resignation is effective from the closing of business hours on June 12, 2026.
The disclosure was made under Regulation 30 of the SEBI (LODR) Regulations, 2015.
The transition involves a key Senior Management Personnel (SMP) position within the company.

💡 Investors should monitor for the appointment of a new head of supply chain to ensure operational continuity. This is a routine management change and does not require immediate portfolio adjustments.

JB Chemicals to Hold 50th AGM on June 17, 2026; Releases FY26 Integrated Annual Report

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 May 2026, 06:34 PM

JB Chemicals & Pharmaceuticals Limited has scheduled its 50th Annual General Meeting (AGM) for June 17, 2026, at 3:00 PM IST via video conferencing. The company has released its Integrated Annual Report for the financial year 2025-26. This specific disclosure pertains to the dispatch of letters to shareholders who have not registered their email addresses, providing them with web links to access the report and AGM notice. The move ensures compliance with SEBI Listing Obligations and Disclosure Requirements.

50th Annual General Meeting scheduled for June 17, 2026, at 3:00 PM IST.
Integrated Annual Report for the financial year 2025-26 is now available for public access.
AGM to be conducted virtually through Video Conference (VC) or Other Audio-Visual Means (OAVM).
Letters dispatched to shareholders with unregistered email IDs to provide digital access links.
Compliance maintained under Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015.

💡 Investors should download and review the Integrated Annual Report for FY 2025-26 to assess the company's strategic direction and financial health. Shareholders are also advised to update their email IDs with the RTA or Depository Participants for seamless future communication.

JBCHEPHARM to Hold 50th AGM on June 17; Final Dividend of ₹9.30 per Share Proposed

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 25 May 2026, 05:03 PM

JB Chemicals & Pharmaceuticals Limited has scheduled its 50th Annual General Meeting for June 17, 2026. The company has proposed a final dividend of ₹9.30 per equity share for FY 2025-26, which follows an interim dividend of ₹12.70 already paid. This brings the total dividend for the fiscal year to ₹22.00 per share. Shareholders must hold the stock by the record date of May 29, 2026, to be eligible for the final payout.

50th Annual General Meeting scheduled for June 17, 2026, via video conferencing
Proposed final dividend of ₹9.30 per equity share for the financial year 2025-26
Total dividend for FY26 stands at ₹22.00 per share, including ₹12.70 interim dividend
Record date for final dividend eligibility is fixed as May 29, 2026
Remote e-voting period is set from June 14 to June 16, 2026

💡 Investors seeking the final dividend of ₹9.30 should ensure they hold the shares before the record date of May 29, 2026. Shareholders are also encouraged to participate in the virtual AGM to stay updated on management's outlook for the next fiscal year.

JB Chemicals Sets May 29, 2026, as Record Date for Final Dividend FY 2025-26

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 21 May 2026, 06:35 PM

JB Chemicals & Pharmaceuticals Limited has officially fixed May 29, 2026, as the record date for determining shareholder eligibility for the final dividend of the financial year 2025-26. This corporate action follows the company's regulatory filing under SEBI Listing Obligations and Disclosure Requirements. Only those shareholders whose names appear in the company's records or as beneficial owners by the end of the record date will be eligible for the payout. The announcement confirms the timeline for the distribution of profits to its investors for the concluded fiscal year.

Record date for final dividend eligibility is fixed as May 29, 2026.
The dividend pertains to the financial year 2025-26 performance.
Compliance confirmed under Regulation 42 of SEBI (LODR) Regulations, 2015.
Eligibility applies to all beneficial owners and shareholders as of the specified date.

💡 Investors seeking to qualify for the dividend should ensure they purchase or hold the stock before the ex-dividend date, which typically precedes the record date. Existing shareholders should verify their holdings to ensure they are registered as beneficial owners by May 29.

View All JBCHEPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Overall revenue grew 8% YoY to INR 1,085 Cr in Q2 FY26. Domestic formulations grew 9% to INR 644 Cr. The CDMO segment reported robust growth of 20% to INR 113 Cr, while International Formulations grew 2% to INR 306 Cr. For the first nine months of fiscal 2025, revenue grew 13% to INR 2,969 Cr.

Geographic Revenue Split

The revenue mix for H1 FY26 was 61% Domestic and 39% International, compared to a 59%/41% split in H1 FY25. International markets include Russia (strong growth), USA, UK, South Africa, Australia, Canada, Africa, South-east Asia, and the Middle East.

Profitability Margins

Gross margins improved by 200 bps to 68.2% in Q2 FY26 from 66.2% YoY, driven by a favorable product mix and price growth. Net profit grew 19% YoY to INR 208 Cr. Operating margins are expected to remain healthy at 26-28% over the medium term.

EBITDA Margin

Operating EBITDA margin (excluding non-cash ESOP) was 29.4% in Q2 FY26, up 100 bps from 28.4% YoY. Operating EBITDA reached INR 319 Cr, a 12% increase, reflecting strong emphasis on cost discipline and execution excellence.

Capital Expenditure

The company plans an annual organic maintenance capex of ~INR 100 Cr. Net capex addition for H1 FY26 was INR 46 Cr compared to INR 49 Cr in H1 FY25. A significant cash consideration of $116 million (approx. INR 970 Cr) is due to Novartis by December 31, 2026, for a Trademark License Agreement.

Credit Rating & Borrowing

The company maintains a healthy financial risk profile with an adjusted gearing of 0.01 times as of March 31, 2025. Gross debt was reduced to INR 7 Cr as of September 30, 2025, from INR 14 Cr in March 2025. Interest coverage ratios are exceptionally high at over 80 times.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) are the primary raw materials. While specific cost percentages per API are not disclosed, the company noted anticipated increases in API costs, leading to strategic inventory building.

Import Sources

Not specifically disclosed in the documents, though the company operates manufacturing units in Ankleshwar and exports to regulated markets like the US and Europe.

Capacity Expansion

Planned organic capex of ~INR 100 Cr annually is focused on maintenance and efficiency. The company is also integrating the acquired ophthalmology portfolio, which is expected to trigger a perpetual license in December 2026.

Raw Material Costs

Raw material costs are managed through cost-optimization efforts and strategic inventory management. Gross margins of 68.2% suggest raw material and direct production costs represent approximately 31.8% of revenue.

Manufacturing Efficiency

Efficiency is driven by a focus on 'progressive' portfolios (65-70% of presence) and chronic therapies. The company is a top 5 global CDMO for lozenges, benefiting from high-standard global approvals.

📈 Strategic Growth

Expected Growth Rate

11-13%

Growth Strategy

Growth will be driven by outperforming the Indian Pharma Market (IPM) with a target of 12-14% domestic growth, ramping up the CDMO business (which grew 20% in Q2 FY26), and leveraging past acquisitions like Sanzyme, Azmarda, and Razel. The company also expects a significant margin boost from the ophthalmology portfolio starting in 2027.

Products & Services

The company sells pharmaceutical formulations (tablets, capsules, injectables), lozenges, and Active Pharmaceutical Ingredients (APIs). Key therapeutic areas include chronic, progressive, and ophthalmology portfolios.

Brand Portfolio

Razel (Cardiovascular), Azmarda (Heart failure), Sanzyme (Probiotics), and various brands acquired from Dr. Reddy’s and Novartis.

New Products/Services

New product launches and the ramp-up of the recently acquired ophthalmology portfolio are expected to be major contributors. The ophthalmology segment is projected to provide a significant gross margin improvement from CY 2027 onwards.

Market Expansion

Focusing on the 'progressive' portfolio (65-70% of current business) and expanding the CDMO lozenges business globally. Russia remains a key growth market in the international segment.

Market Share & Ranking

Ranked 20th in chronic therapies as of Dec 2024 (up from 25th). It is the fastest-growing company among the top 25 in the Indian Pharmaceutical Market (IPM).

Strategic Alliances

Trademark License Agreement with Novartis Switzerland for the ophthalmology portfolio; strategic acquisitions from Sanzyme Pvt Ltd and Dr. Reddy’s Laboratories.

🌍 External Factors

Industry Trends

The Indian Pharma Market (IPM) is growing at 8%, while JB Pharma is growing at 12%, indicating a shift toward high-growth chronic and progressive therapies. The CDMO sector for specialized forms like lozenges is expanding globally.

Competitive Landscape

Faces intense competition from other large Indian pharma players and global generic manufacturers. Competitors include the top 25 companies in the IPM.

Competitive Moat

Moat is built on a top 5 global position in lozenges CDMO, strong brand equity in chronic therapies (Razel, Azmarda), and a high-margin 'progressive' portfolio. These are sustainable due to high regulatory barriers and established physician trust.

Macro Economic Sensitivity

Sensitive to domestic healthcare regulatory changes and pricing controls. Domestic growth of 12% vs IPM growth of 8% shows high resilience to general market trends.

Consumer Behavior

Shift toward chronic disease management and preventive healthcare is driving demand for the company's cardiovascular and probiotic portfolios.

Geopolitical Risks

Exposure to the Russian market, which showed strong growth in Q2 FY26, carries inherent geopolitical risk. Trade barriers in regulated markets (US/Europe) could also impact the CDMO business.

⚖️ Regulatory & Governance

Industry Regulations

Subject to stringent manufacturing standards from global regulators (US FDA, Europe) for its CDMO business and domestic pricing controls for formulations.

Legal Contingencies

The company is managing a non-cash ESOP charge with a remaining balance of approximately INR 47 Cr. No specific court cases or values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

The potential acquisition of a stake in JBCPL by Torrent Pharmaceuticals is a key monitorable factor that could lead to management changes and impact strategic direction.